Artemether-lumefantrine co-administration with antiretrovirals: Population pharmacokinetics and dosing implications

British Journal of Clinical Pharmacology

Volumn 79, Issue 4, 2015, Pages 636-649

  Hoglund, Richard M ^a   Byakika Kibwika, Pauline ^b   Lamorde, Mohammed ^b   Merry, Concepta ^b   Ashton, Michael ^a   Hanpithakpong, Warunee ^c   Day, Nicholas P J ^c,d   White, Nicholas J ^c,d   Äbelö, Angela ^a   Tarning, Joel ^c,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

artemether lumefantrine; drug drug interaction; efavirenz; lopinavir ritonavir; nevirapine; population pharmacokinetics

Indexed keywords

ARTEMETHER; BENFLUMETOL; DESBUTYL LUMEFANTRINE; DIHYDROARTEMISININ; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALARIA; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BIOAVAILABILITY; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG INTERACTION; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTI-HIV AGENTS; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84925424409     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12529     Document Type: Article

References (53)

1. WHO. World Malaria Report: 2013. Geneva, Switzerland: WHO, 2013.
2. WHO. Progress Report 2011: Global HIV/AIDS Response. Geneva, Switzerland: WHO, 2011.
3. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF,. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15: 899-906.
4. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, Omoding N, Okongo M, Malamba S, Ojwiya A,. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-1056.
5. Ali S, Najmi MH, Tarning J, Lindegardh N,. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malar J 2010; 9: 275.
6. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS,. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000; 10: 141-151.
7. Van Agtmael MA, Gupta V, van der Graaf CA, van Boxtel CJ,. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther 1999; 66: 408-414.
8. Tarning J, Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Nuengchamnong N, Nosten F, Day NPJ, White NJ, Guerin PJ, Lindegardh N,. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J 2012; 11: 293.
9. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P,. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 2000; 39: 255-270.
10. Kokwaro G, Mwai L, Nzila A,. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007; 8: 75-94.
11. Ilett KF, Ethell BT, Maggs JL, Davis TME, Batty KT, Burchell B, Binh TQ, Thu LTA, Hung NC, Pirmohamed M, Park BK, Edwards G,. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002; 30: 1005-1012.
12. Van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ,. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12: 151-158.
13. Ashley EA, Stepniewska K, Lindegårdh N, McGready R, Annerberg A, Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S, Wilahphaingern J, Singhasivanon P, White NJ, Nosten F,. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health 2007; 12: 201-208.
14. Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, Guerin PJ, Piola P,. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother 2013; 57: 5096-5103.
15. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D,. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002; 54: 485-492.
16. Wong RPM, Salman S, Ilett KF, Siba PM, Mueller I, Davis TME,. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 2011; 55: 1194-1198.
17. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard G-D, Andriano K, Lefèvre G, De Palacios PI, Genton B,. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2008; 78: 241-247.
18. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, Mueller I, Davis TME,. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 2011; 55: 5306-5313.
19. Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, Telenti A, Eap CB,. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865-873.
20. Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, Gigliotti M, Robinson P, Azzam S, Keirns J,. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther 1999; 65: 137.
21. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR,. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49: 513-519.
22. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH,. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78: 132-142.
23. Burhenne J, Matthée A-K, Pasáková I, Röder C, Heinrich T, Haefeli WE, Mikus G, Weiss J,. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010; 54: 4185-4191.
24. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D,. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-556.
25. Oswald S, Meyer zu Schwabedissen HE, Nassif A, Modess C, Desta Z, Ogburn ET, Mostertz J, Keiser M, Jia J, Hubeny A, Ulrich A, Runge D, Marinova M, Lütjohann D, Kroemer HK, Siegmund W,. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther 2012; 91: 506-513.
26. Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ,. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-1045.
27. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein CE, Rublein JC, Kashuba ADM,. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52-60.
28. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG,. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005; 33: 1729-1739.
29. Porter KA, Cole SR, Eron JJ, Zheng Y, Hughes MD, Lockman S, Poole C, Skinner-Adams TS, Hosseinipour M, Shaffer D, D'Amico R, Sawe FK, Siika A, Stringer E, Currier JS, Chipato T, Salata R, McCarthy JS, Meshnick SR,. HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother 2012; 56: 995-1000.
30. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ,. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005; 49: 2983-2985.
31. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR,. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012; 367: 2110-2118.
32. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT,. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424-429.
33. Kredo T, Mauff K, Van der Walt JS, Wiesner L, Maartens G, Cohen K, Smith P, Barnes KI,. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55: 5616-5623.
34. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT,. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr 2012; 61: 310-316.
35. Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, Hanpithakpong W, Pakker N, Dorlo TPC, Tarning J, Lindegardh N, de Vries PJ, Back D, Khoo S, Merry C,. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 1217-1223.
36. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, Katabira E, Ntale M, Pakker N, Ryan M, Hanpithakpong W, Tarning J, Lindegardh N, de Vries PJ, Khoo S, Back D, Merry C,. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 2213-2221.
37. Annerberg A, Singtoroj T, Tipmanee P, White NJ, Day NPJ, Lindegårdh N,. High throughput assay for the determination of lumefantrine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 822: 330-333.
38. Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NPJ, Lindegardh N,. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 876: 61-68.
39. Blessborn D, Römsing S, Annerberg A, Sundquist D, Björkman A, Lindegardh N, Bergqvist Y,. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal 2007; 45: 282-287.
40. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001.
41. Beal SL, Sheiner LB,. Estimating population kinetics. Crit Rev Biomed Eng 1982/01/01 ed. 1982; 8: 195-222.
42. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR,. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-79.
43. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999/04/09 ed. 1999; 58: 51-64.
44. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005/07/19 ed. 2005; 79: 241-257.
45. Beal SL,. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
46. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007/07/27 ed. 2007; 34: 711-726.
47. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A,. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384-394.
48. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13: 143-151.
49. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NP, Stepniewska K, Singhasivanon P, White NJ, Nosten F,. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009; 01 edn. 53: 3837-3846.
50. Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, Lindegårdh N, Nosten F, Day NPJ, White NJ, Guerin PJ, Tarning J,. Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. CPT Pharmacometrics Syst Pharmacol 2013; 2: e83.
51. Ezzet F, Mull R, Karbwang J,. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553-561.
52. Mordi MN, Mansor SM, Navaratnam V, Wernsdorfer WH,. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol 1997; 43: 363-365.
53. Price RN, Uhlemann A-C, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJC, Krishna S, White NJ, Nosten F,. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42: 1570-1577.